Abstract microRNAs (miRNA) are present in skeletal muscle and play important roles in regulating gene expression. Previous research identified miR-22-3p and miR-127 as differentially regulated during muscle hypertrophy and in vitro experiments found that antagomir-22-3p and mimic-127 enhanced satellite cell proliferation. The objective of this study was to test in vivo intramuscular injection of agomiR-127 or antagomir-22-3p in the longissimus muscle (LM) on miRNA and target mRNA expression in intrauterine growth restricted lambs. Pregnant ewes (n = 18) with twins were nutrient restricted (60%) from gestational d 85 to parturition. On d 2 of age, lambs were randomly selected and assigned to one of two miRNA treatments, 1) agomiR-127 (AGO127, 100 nM, n = 9) to assess gain of function or 2) antagomiR-22-3p (ANT22, 500 nM, n = 9) to assess loss of function. AgomiR and antagomiR technologies are chemically modified miRNA mimics or inhibitors that do not require transfection for in vivo use. AgomiR-127 or antagomir-22-3p were reconstituted in phosphate buffered saline (PBS) and injected into the center of the LM on the left side every 3-d starting at the 10th rib and moving posterior by 1.27 cm at each injection for a total of 7 injections. A sham control treatment (SHAM127 or SHAM22) of PBS was administered following the same protocol in the right LM to serve as the in-animal control. Lambs were harvested 4 d after the last injection and samples were collected from the injection region of each LM for miRNA and mRNA expression, histology, and proteomic analyses. Data were analyzed using paired t-tests to compare each miRNA treatment to its SHAM within animal. AGO127 up-regulated (P = 0.0071) miR-127 expression compared with SHAM127. mRNA expression of PAX7 and MSTN were up-regulated (P < 0.05) and IGFBP2 expression was down-regulated (P < 0.05) for AGO127 compared with SHAM127. Both protein and DNA content of AGO127 were increased (P < 0.05) but the ratio of protein to DNA did not change (P > 0.05). Proteomic analyses found 11 proteins that were differentially expressed for AGO127 compared with SHAM127. ANT22 down-regulated (P = 0.0024) miR-22-3p expression from SHAM22. Expression of predicted mRNA targets of miR-22-3p (ACVR2a, ACVR2b, SIRT1), myosin heavy chain isoforms (MyHCI, MyHCIIa, MyHCIIx), and other myogenic genes (MAPK6, IGF1, MyoG) were also altered (P < 0.05) in the LM compared with SHAM22. DNA content and the protein to DNA ratio was greater (P < 0.05) in ANT22 than SHAM22. Proteomic analyses identified nine proteins that were differentially expressed (P < 0.05) for ANT22. The direct injection of agomiR and antagomir technologies in the LM up- and down-regulated expression, respectively, for the miRNA of interest, which altered mRNA expression of predicted targets, protein abundance and muscle fiber type.
Read full abstract